Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 2.6M | $33.1M | $12.74 | Jul 15, 2022 | By Alpine ImmunoSciences, L.P. |
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 238K | $3.03M | $12.74 | Jul 15, 2022 | Direct |
Elicio Therapeutics, Inc. | Director | Pre-Funded Warrants | 50K | $250K | $4.99 | Jun 28, 2024 | Direct |
Elicio Therapeutics, Inc. | Director | Pre-Funded Warrants | 50K | $250K | $4.99 | Jun 28, 2024 | Indirect |
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 18.6K | $237K | $12.74 | Jul 15, 2022 | By Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan |
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 18.6K | $237K | $12.74 | Jul 15, 2022 | By Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan |
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Stock Option (Right to buy) | 70K | Jul 15, 2022 | Direct | ||
Elicio Therapeutics, Inc. | Director | Common Warrants | 50K | Jun 28, 2024 | Direct | ||
Elicio Therapeutics, Inc. | Director | Common Warrants | 50K | Jun 28, 2024 | Indirect | ||
Elicio Therapeutics, Inc. | Director | Stock Option (right to buy) | 4.1K | Dec 28, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ELTX | Elicio Therapeutics, Inc. | Jun 28, 2024 | 8 | $998K | 4 | Jul 2, 2024 | Director |
ELTX | Elicio Therapeutics, Inc. | Dec 28, 2023 | 1 | $0 | 4 | Dec 29, 2023 | Director |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jul 15, 2022 | 2 | $0 | 4 | Jul 19, 2022 | Director, 10%+ Owner |
ELTX | Angion Biomedica Corp. | May 25, 2022 | 1 | $14.1K | 4 | May 27, 2022 | Officer, Director |
ELTX | Angion Biomedica Corp. | May 20, 2022 | 2 | $101K | 4 | May 25, 2022 | President and Chief Executive Officer and Director, Director |
ELTX | Angion Biomedica Corp. | Mar 3, 2022 | 2 | $0 | 4 | Mar 4, 2022 | President and Chief Executive Officer |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jan 3, 2022 | 1 | $0 | 4 | Jan 4, 2022 | Director, 10%+ Owner |
ELTX | Angion Biomedica Corp. | Dec 27, 2021 | 2 | $730K | 4 | Dec 29, 2021 | President and Chief Executive Officer and Director, Director |
ELTX | Angion Biomedica Corp. | Dec 20, 2021 | 1 | $8.98K | 4 | Dec 22, 2021 | President and Chief Executive Officer and Director, Director |
ELTX | Angion Biomedica Corp. | Dec 16, 2021 | 2 | $106K | 4 | Dec 20, 2021 | President and Chief Executive Officer and Director, Director |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Sep 17, 2021 | 1 | -$3.76M | 4 | Sep 21, 2021 | Director, 10%+ Owner |
ELTX | Angion Biomedica Corp. | Jun 24, 2021 | 2 | -$379K | 4 | Dec 17, 2021 | President and Chief Executive Officer and Director, Director |
ELTX | Angion Biomedica Corp. | Feb 9, 2021 | 4 | $4.59K | 4/A | May 27, 2022 | President and Chief Executive Officer and Director, Director |